PJSC Farmak, the Ukrainian pharmaceutical producer, saw its net profit rise by 29.91%, to UAH 839.09 million in 2017 against UAH 677.202 million in 2016, the company reported in the information disclosure system of the National Commission on Securities and the Stock Market. The company shareholders plan to discuss the results of the company’s work at a general meeting scheduled for April 19. The company’s assets for the period increased by 11%, to UAH 4.86 billion.
According to the state register, the ultimate beneficiary owner of PJSC Farmak is head of its supervisory board Filia Zhebrovska. As reported, in 2017 Farmak increased sales in the retail pharmaceutical market by 21% in monetary terms.
PJSC Farmak is a Ukrainian manufacturer of medicines at the European level, the leader of the pharmaceutical market of Ukraine in terms of sales. Farmak exports products to 20 countries. The company’s portfolio includes 220 product dossiers. Annually the company brings up to 20 new products to the market.
